{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:35:27Z","timestamp":1789320927599,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eli Lilly Trading Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary Sjogren\u2019s syndrome (pSS) is a systemic autoimmune disease involving multiple organ systems. The Janus kinase\/signal transduction and activator of transcription (JAK\/STAT) signaling pathway is a key pathway involving the pathogenesis of pSS. Baricitinib, a selective JAK1 and JAK2 inhibitor, has been approved for treatment of active rheumatoid arthritis and reported in treatment of some other autoimmune diseases including systemic lupus erythematosus. We have found that baricitinib might be effective and safe in pSS in a pilot study. However, there is no published clinical evidence of baricitinib in pSS. Hence, we conducted this randomized study to further explore the efficacy and safety of baricitinib in pSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a multi-center, prospective, open-label, randomized study to compare the efficacy of baricitinib\u2009+\u2009hydroxychloroquine (HCQ) with HCQ alone in pSS patients. We plan to involve 87 active pSS patients with European League Against Rheumatism pSS disease activity index (ESSDAI)\u2009\u2265\u20095 from eight different tertiary centers in China. Patients will be randomized (2:1) to receive baricitinib 4\u00a0mg per day\u2009+\u2009HCQ 400\u00a0mg per day or HCQ 400\u00a0mg per day alone. We will switch HCQ to baricitinib\u2009+\u2009HCQ if the patient in the latter group has no ESSDAI response at week 12. The final evaluation will be at week 24. The primary endpoint is the percentage of ESSDAI response, or minimal clinically important improvement (MCII), which was defined as an improvement of ESSDAI at least three points at week 12. The secondary endpoints include EULAR pSS patient-reported index (ESSPRI) response, change of Physician\u2019s Global Assessment (PGA) score, serological activity parameters, salivary gland function test, and focus score on labial salivary gland biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first randomized controlled study to evaluate the clinical efficacy and safety of baricitinib in pSS. We hope that the result of this study can provide more reliable evidence of the efficacy and safety of baricitinib in pSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT05016297. Registered on 19 Aug 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07087-5","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T06:40:08Z","timestamp":1676961608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren\u2019s syndrome patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"7087_CR1","doi-asserted-by":"publisher","first-page":"6309219","DOI":"10.1155\/2016\/6309219","volume":"2016","author":"ML Diller","year":"2016","unstructured":"Diller ML, Kudchadkar RR, Delman KA, Lawson DH, Ford ML. Balancing inflammation: the link between Th17 and regulatory T Cells. Mediators Inflamm. 2016;2016:6309219.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"7087_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/jcm6070065","volume":"6","author":"K Matsui","year":"2017","unstructured":"Matsui K, Sano H. T helper 17 cells in primary Sjogren\u2019s syndrome. J Clin Med. 2017;6(7):65.","journal-title":"J Clin Med."},{"issue":"4","key":"7087_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10067-013-2476-z","volume":"33","author":"Y Fei","year":"2014","unstructured":"Fei Y, Zhang W, Lin D, Wu C, Li M, Zhao Y, et al. Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjogren\u2019s syndrome. Clin Rheumatol. 2014;33(4):523\u20139.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"7087_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","volume":"53","author":"F Ciccia","year":"2014","unstructured":"Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjogren\u2019s syndrome. Rheumatology (Oxford). 2014;53(7):1313\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"7087_CR5","doi-asserted-by":"publisher","first-page":"e0173301","DOI":"10.1371\/journal.pone.0173301","volume":"12","author":"R Liu","year":"2017","unstructured":"Liu R, Gao C, Chen H, Li Y, Jin Y, Qi H. Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease. PLoS ONE. 2017;12(4):e0173301.","journal-title":"PLoS ONE"},{"key":"7087_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaut.2017.11.003","volume":"87","author":"GM Verstappen","year":"2018","unstructured":"Verstappen GM, Corneth OBJ, Bootsma H, Kroese FGM. Th17 cells in primary Sjogren\u2019s syndrome: pathogenicity and plasticity. J Autoimmun. 2018;87:16\u201325.","journal-title":"J Autoimmun"},{"issue":"3","key":"7087_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, Li J, Wang Q, Tian X, et al. JAK Inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59(3):334\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"7087_CR8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.celrep.2017.05.013","volume":"19","author":"SK Tripathi","year":"2017","unstructured":"Tripathi SK, Chen Z, Larjo A, Kanduri K, Nousiainen K, Aijo T, et al. Genome-wide analysis of STAT3-mediated transcription during early human Th17 cell differentiation. Cell Rep. 2017;19(9):1888\u2013901.","journal-title":"Cell Rep"},{"issue":"1","key":"7087_CR9","doi-asserted-by":"publisher","first-page":"15645","DOI":"10.1038\/s41598-018-34026-1","volume":"8","author":"A Hammitzsch","year":"2018","unstructured":"Hammitzsch A, Chen L, de Wit J, Al-Mossawi MH, Ridley A, Sekine T, et al. Inhibiting ex-vivo Th17 responses in ankylosing spondylitis by targeting Janus kinases. Sci Rep. 2018;8(1):15645.","journal-title":"Sci Rep"},{"issue":"7","key":"7087_CR10","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","volume":"193","author":"MG Works","year":"2014","unstructured":"Works MG, Yin F, Yin CC, Yiu Y, Shew K, Tran TT, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis. J Immunol. 2014;193(7):3278\u201387.","journal-title":"J Immunol"},{"issue":"5","key":"7087_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jbspin.2015.09.002","volume":"83","author":"H Wu","year":"2016","unstructured":"Wu H, Yan S, Chen J, Luo X, Li P, Jia X, et al. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 2016;83(5):525\u201332.","journal-title":"Joint Bone Spine"},{"issue":"9","key":"7087_CR12","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.4049\/jimmunol.1300514","volume":"192","author":"JS Park","year":"2014","unstructured":"Park JS, Lee J, Lim MA, Kim EK, Kim SM, Ryu JG, et al. JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells. J Immunol. 2014;192(9):4417\u201324.","journal-title":"J Immunol"},{"issue":"4","key":"7087_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","volume":"14","author":"TLW Muskardin","year":"2018","unstructured":"Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214\u201328.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"7087_CR14","first-page":"185","volume":"37118","author":"N Marketos","year":"2019","unstructured":"Marketos N, Cinoku I, Rapti A, Mavragani CP. Type I interferon signature in Sj\u00f6gren\u2019s syndrome: pathophysiological and clinical implications. Clin Exp Rheumatol. 2019;37118(3):185\u201391.","journal-title":"Clin Exp Rheumatol."},{"issue":"12","key":"7087_CR15","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/art.40589","volume":"70","author":"J Lee","year":"2018","unstructured":"Lee J, Lee J, Kwok SK, Baek S, Jang SG, Hong SM, et al. JAK-1 Inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sjogren\u2019s syndrome. Arthritis Rheumatol. 2018;70(12):2057\u201366.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"7087_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12016-019-08743-y","volume":"58","author":"A Charras","year":"2020","unstructured":"Charras A, Arvaniti P, Le Dantec C, Arleevskaya MI, Zachou K, Dalekos GN, et al. JAK inhibitors suppress innate epigenetic reprogramming: a promise for patients with Sjogren\u2019s syndrome. Clin Rev Allergy Immunol. 2020;58(2):182\u201393.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"7087_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","volume":"44","author":"K Aota","year":"2021","unstructured":"Aota K, Yamanoi T, Kani K, Ono S, Momota Y, Azuma M. Inhibition of JAK-STAT signaling by baricitinib reduces interferon-gamma-induced CXCL10 production in human salivary gland ductal cells. Inflammation. 2021;44(1):206\u201316.","journal-title":"Inflammation"},{"issue":"2","key":"7087_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren\u2019s syndrome with EULAR primary Sjogren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7087_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"10143","key":"7087_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222\u201331.","journal-title":"Lancet"},{"issue":"3","key":"7087_CR21","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1093\/brain\/awz005","volume":"142","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain J Neurol. 2019;142(3):e8.","journal-title":"Brain J Neurol"},{"issue":"8","key":"7087_CR22","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s10067-015-3003-1","volume":"34","author":"M Li","year":"2015","unstructured":"Li M, Tian X, Zhang W, Leng X, Zeng X. CRDC: a Chinese rheumatology research platform. Clin Rheumatol. 2015;34(8):1347\u201352.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"7087_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/annrheumdis-2016-210448","volume":"76","author":"BA Fisher","year":"2017","unstructured":"Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2017;76(7):1161\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7087_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/annrheumdis-2021-222053","volume":"81","author":"W Bai","year":"2022","unstructured":"Bai W, Liu H, Dou L, Yang Y, Leng X, Li M, et al. Pilot study of baricitinib for active Sjogren\u2019s syndrome. Ann Rheum Dis. 2022;81(7):1050\u20132.","journal-title":"Ann Rheum Dis"},{"key":"7087_CR25","doi-asserted-by":"crossref","unstructured":"Fornaro M, Coladonato L, Venerito V, Cacciapaglia F, Lopalco G, Iannone F. Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2020;59(5):1188.","DOI":"10.1093\/rheumatology\/kez442"},{"issue":"5","key":"7087_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/annrheumdis-2019-216571","volume":"79","author":"K Maeshima","year":"2020","unstructured":"Maeshima K, Shibata H. Efficacy of JAK 1\/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus. Ann Rheum Dis. 2020;79(5):674\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7087_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/annrheumdis-2018-213197","volume":"77","author":"MK Sarkar","year":"2018","unstructured":"Sarkar MK, Hile GA, Tsoi LC, Xing X, Liu J, Liang Y, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7087_CR28","doi-asserted-by":"publisher","first-page":"e000424","DOI":"10.1136\/lupus-2020-000424","volume":"7","author":"T Dorner","year":"2020","unstructured":"Dorner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, et al. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med. 2020;7(1):e000424.","journal-title":"Lupus Sci Med."},{"issue":"7","key":"7087_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1186\/s13063-023-07546-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07087-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07087-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T02:07:20Z","timestamp":1690855640000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07087-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7087"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07087-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1406859\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-023-07546-z","URL":"https:\/\/doi.org\/10.1186\/s13063-023-07546-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital (approval numbers: HS-3023D), and written informed consent was obtained from all the patients involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"This manuscript does not contain individual personal data from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"112"}}